Dupilumab efficacy in chronic rhinosinusitis with nasal polyps from SINUS‐52 is unaffected by eosinophilic status-Reference-Cited by-同舟云学术

Dupilumab efficacy in chronic rhinosinusitis with nasal polyps from SINUS‐52 is unaffected by eosinophilic status

Published:2021-06-04 Issue:1 Volume:77 Page:186-196
ISSN:0105-4538
Container-title:Allergy
language:en
Short-container-title:Allergy

Author:

Fujieda Shigeharu¹^ORCID,Matsune Shoji²,Takeno Sachio³,Ohta Nobuo⁴,Asako Mikiya⁵,Bachert Claus⁶⁷^ORCID,Inoue Tomoyuki⁸,Takahashi Yoshinori⁸,Fujita Hiroyuki⁸,Deniz Yamo⁹,Rowe Paul¹⁰,Ortiz Benjamin⁹,Li Yongtao¹⁰,Mannent Leda P.¹¹

Affiliation:

1. Department of Otorhinolaryngology‐Head & Neck Surgery Fukui Japan

2. Nippon Medical School Musashi Kosugi Hospital Kanagawa Japan

3. Department of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Biomedical and Health Sciences Hiroshima University Hiroshima Japan

4. Department of Otolaryngology Tohoku Medical and Pharmaceutical University Sendai Japan

5. Department of Otolaryngology Kansai Medical University Osaka Japan

6. Department of Ear, Nose, and Throat Science Ghent University Ghent Belgium

7. Department of Clinical Science, Intervention and Technology Karolinska Institutet Stockholm Sweden

8. Sanofi K.K. Tokyo Japan

9. Regeneron Pharmaceuticals, Inc. Tarrytown NY USA

10. Sanofi Bridgewater NJ USA

11. Sanofi France Chilly‐Mazarin, Île‐de‐France France